Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Global Blood shelves lung disease program on weak study results

  • Adam Feuerstein

By Adam Feuerstein Oct. 23, 2017

Reprints
Red blood cells
Red blood cells Annie Cavanagh/Wellcome Images

Global Blood Therapeutics (GBT) is discontinuing an early-stage program to treat patients with idiopathic pulmonary fibrosis, a progressive and fatal lung disease.

Across two small clinical trials, Global Blood’s lead drug, GBT440, failed to raise oxygen saturation levels high enough in patients to justify moving the idiopathic pulmonary fibrosis (IPF) program forward, the company said Monday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Top FDA official: Agency needs to start using accelerated…
Top FDA official: Agency needs to start using accelerated approval for gene therapies
‘Three Identical Strangers’: It’s not too late to address…
‘Three Identical Strangers’: It’s not too late to address the ethical violations
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Pharmalittle: FDA official wants to use accelerated approval for…
Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax…
A new Medicare ruling could give virtual reality companies…
A new Medicare ruling could give virtual reality companies an easier path to payment
8 burning questions Bernie Sanders and other senators should…
8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel

Recommended Stories